| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 2.78% |
| NAV | ₹80.4 (21 May 2019) |
|---|---|
| Fund Started | 27 May 1999 |
| Fund Size | ₹437 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Alkem Laboratories Ltd. | Healthcare | Equity | 8.6% |
| Torrent Pharmaceuticals Ltd. | Healthcare | Equity | 8.1% |
| Cipla Ltd. | Healthcare | Equity | 7.8% |
| Pfizer Ltd. | Healthcare | Equity | 6.7% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 6.3% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 5.8% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 5.8% |
| Ajanta Pharma Ltd. | Healthcare | Equity | 5.2% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 4.8% |
| Sanofi India Ltd. | Healthcare | Equity | 4.8% |
UTI Mutual Fund started their mutual fund on 01/02/2003 and its managing total assets of ₹1,50,669 Cr. Its ranked at 6 as per total assets at end of 30th Sep 2017.
UTI Mutual Fund was carved out of the erstwhile Unit Trust of India as a SEBI registered mutual fund from 1 February 2003. The Unit Trust of India Act 1963 was repealed, paving way for the bifurcation of UTI into – Specified Undertaking of Unit Trust of India; and UTI Mutual Fund. UTI AMC, India’s most trusted Wealth creators and always has the interest of its investors in its heart. The AMC has completed 50 years as India’s leading Financial service institution and was a sole vehicle of capital market investment for Indian Citizens till the early 90’s. The institution has shown great resilience and has grown from strength to strength overcoming economic turbulence and global turnarounds. This AMC has contributed immensely to industrial and capital growth in the Indian market. It has led transformative initiatives like developmental financial institutions, rural outreach programs and financial products and services.